Aging
Conditions
Keywords
Epigenetic aging, Microbiome, Quality of Life, Overweight and Obesity
Brief summary
The primary purpose of this study is to assess changes in epigenetic markers of aging and physiological parameters in overweight older adults consuming a mixed greens-based supplement over a 30-day period in a randomized crossover design.
Detailed description
Investigators will recruit 20 overweight/obese but otherwise healthy participants aged 50-65. Participants will be randomized to consume the greens-based supplement each morning for the first 30 days or second 30 days of the study. Usual diet, physical activity, and sleep patterns will be encouraged and monitored during the duration of the study. Phlebotomy will be conducted at baseline, 30-day crossover, and 60-day follow-up to assess DNA methylation in peripheral blood mononuclear cells. Visceral and total body fat, stool microbiome composition, and actigraphy will also be assessed.
Interventions
DIETARY_SUPPLEMENTGreens-based Supplement
Participant will consume one serving of greens-based supplement per day in the morning, for 30 days.
Sponsors
Brickhouse Nutrition
Auburn University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Intervention model description
Randomized crossover trial
Eligibility
Sex/Gender
ALL
Age
50 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Men and women of any ethnicity (women must be postmenopausal) * Body Mass Index \> 30 kg/m\^2 * Low habitual dark green leafy vegetable consumption * Willing to adhere to study protocol and measures * Willing to communicate via smartphone technology * Able to read, write and speak English
Exclusion criteria
* Overt cardiometabolic diseases such heart attack, stroke, diabetes, insulin resistance and non-alcoholic fatty liver disease, etc. * Diagnosis of a transient ischemic attack in the 6 months prior to screening * Diagnosis of cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision * Food allergies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in DNA Methylation in Peripheral Blood Mononuclear Cells | Change from day 0 (baseline) to day 30 post intervention supplementation. | Change from Baseline in Epigenetic Aging Profiles (i.e. DNA Methylation), after 30 day intervention. Participants will provide blood samples at their baseline study visit, which occurs before the start of the intervention, and at their visit at the end of the 30th of intervention supplementation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fasting serum low-density lipoproteins (LDL) | Change from day 0 (baseline) to day 30 post intervention supplementation. | Phlebotomy will be obtained while fasted 8+ hours and low-density lipoproteins (LDL) will be measured as part of a comprehensive metabolic panel and reported in mg/dl. Lower concentrations are optimal. |
| Fasting serum blood glucose | Change from day 0 (baseline) to day 30 post intervention supplementation. | Phlebotomy will be obtained while fasted 8+ hours and blood glucose will be measured as part of a comprehensive metabolic panel and reported in mg/dl. Lower concentrations are optimal. |
| Visceral fat percentage | Change from Day 0 (baseline), Day 30 (Crossover/Midpoint ), and Day 60 (end of study) | Change in visceral fat as a percentage of total fat mass as measured by bioelectrical impedance (BIA). Lower values are optimal. |
| Total body fat percentage | Change from Day 0 (baseline), Day 30 (Crossover/Midpoint ), and Day 60 (end of study) | Change in total body fat as a percentage of total fat mass as measured by bioelectrical impedance (BIA). Lower values are optimal. |
| Stool microbiome composition | Change from Day 0 (baseline), Day 30 (Crossover/Midpoint ), and Day 60 (end of study) | 16S changes in microbiome alpha diversity. |
| Fasting serum triglycerides | Change from day 0 (baseline) to day 30 post intervention supplementation. | Phlebotomy will be obtained while fasted 8+ hours and triglycerides will be measured as part of a comprehensive metabolic panel and reported in mg/dl. Lower concentrations are optimal. |
| Breath Methane (ppm) | Change from Day 0 (baseline), Day 30 (Crossover/Midpoint ), and Day 60 (end of study) | Breath methane will be measured via QuinTron BreathTracker SC Analyzer every 30minutes to 1.5 hours on days 21 and 51. Lower levels are optimal. |
| Physical Quality of Life | Change from Baseline (day 0), Crossover/Midpoint (day 30), and End of study (day 60) | The SF-12 PCS (Short Form-12, Physical Component Score) is a health-related quality of life measure that assesses general physical functioning and well-being. SF-12 PCS scores range from 0-100 with higher scores indicating better general physical health. |
| Sleep and Physical Activity- accelerometry | Change from Baseline (day 0), Crossover/Midpoint (day 30), and End of study (day 60) | Average minutes of total daily sleep and physical activity measured via garmin watch. |
| Total caloric intake | Change from Baseline (day 0), Crossover/Midpoint (day 30), and End of study (day 60) | Three 24-hour dietary recalls will be obtained and entered into the and analyzed in the Nutrition Data System for Research (NDSR). |
| Mental Quality of Life | Change from Baseline (day 0), Crossover/Midpoint (day 30), and End of study (day 60) | The SF-12 MCS (Short Form-12, Mental Component Score) is a health-related quality of life measure that assesses general mental health status. SF-12 MCS scores range from 0-100 with higher scores indicating better general mental health. |
| Breath Hydrogen (ppm) | Change from Day 0 (baseline), Day 30 (Crossover/Midpoint ), and Day 60 (end of study) | Breath hydrogen will be measured via QuinTron BreathTracker SC Analyzer every 30 minutes to 1.5 hours on days 21 and 51. Lower levels are optimal. |
Countries
United States
Outcome results
None listed